tbuckley/cabot-search huggingface dataset:
AB0302 Bone texture parameters measured at the hand as predictors of outcome in rheumatoid arthritis
Authors: L. Sparsa, S. Kolta, P. Geusens, K. Briot, C. Roux
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Bone and cartilage loss and destruction is associated with rheumatoid arthritis (RA) and inflammation. There is a need for tools for prediction of potential severe patients with poor outcome. The BMA device (D3A™ Medical Systems, Orleans, France) is a high resolution X-ray technique, used to image bone and joints, and to measure bone texture parameters including the fractal dimension (Hmean). <h3>Objectives</h3> The aims of this study were to evaluate, by BMA analysis, the metacarpal bone texture in a cohort of 165 RA patients with 1 year follow up, and to assess this new parameter according to the activity of RA. <h3>Methods</h3> 165 patients with RA according to ACR criteria were included. They were assessed every 6 months over 1 year, in the context of a prospective study conducted in Maastricht. For this substudy, activity of the disease was assessed by erythrocyte sedimentation rate (ESR), C reactive protein (CRP) and Disease Activity Score (DAS 28) performed at each visit. The bone texture parameters were evaluated on the second and third metacarpal heads of the left hand (MCP2 and MCP3) using BMA device, with standard acquisition at baseline, 6 and 12 months. A single investigator performed all the analyses, with standardized position of regions of interest in the bones. The calculated parameter was Hmean as an approach to bone roughness. <h3>Results</h3> We included 57 men and 108 women, mean age 63.63 years [33-89]. The mean disease duration was 9.67 years [2-36]. Among the 138 cases where rheumatoid factor results were available, 75 were positive and among the 11 cases where anti CCP antibodies were available only 6 were positive. Fifty five patients had erosions on X rays of the hands. The mean DAS28 score was 3.34 [0.63-7.35]. Twenty four patients were receiving bisphosphonate during the study. Hmean was similar in MCP2 and MCP3 at baseline: 0.411±0.038 and 0.412±0.043 respectively; H mean MCP2 was correlated with disease duration (-0.17, p=0.03). There was an increase in H mean MCP2 (+ 1.0% p=0.0004) over 1 year. ESR and CRP were correlated with H mean MCP3 at baseline (-0,15, p=0.055; -0.15 p=0.06) and 6 months (-0.22 p=0.006, -0.25 p=0.002 respectively). DAS was correlated with H mean MCP3 at 6 months (-0.14, p=0.07) and H mean MCP2 at 12 months (-0.16 p=0.04). <h3>Conclusions</h3> This new high resolution digital X-ray device provides bone texture parameters of metacarpal heads in RA patients. This preliminary analysis suggests that these parameters measured at the metacarpal heads are influenced by disease duration and activity. <h3>Disclosure of Interest</h3> None Declared
MYOCARDIAL FUNCTION AND LEFT VENTRICLE AFTERLOAD DURING AND AFTER COMMUNITY-ACQUIRED PNEUMONIA (CAP) IN ELDERLY ADULTS
Authors: Vicente Francisco Corrales-Medina, Girish Dwivedi, Izzah Vasim, Saima Arooj, Maheswara R. Koppula, Swapna Varakantam
Journal: Journal of the American College of Cardiology (2016)
O9.01 * THE ROLE OF GENDER IN CNS TUMOUR INCIDENCE AND SURVIVAL
Authors: R. Mathew, S. Alli, J. Hayes, R. Parslow, J. Goodden, P. Chumas
Journal: Neuro-Oncology (2014)

INTRODUCTION: Evidence exists, in germ cell tumours (GCT) and medulloblastoma subcategories, that gender significantly influences incidence and outcome - perhaps through susceptibility to tumour genesis, and sensitivity to treatment. The role of gender in other CNS tumours is unclear. METHODS: Age-adjusted incidence (2000-2007) and overall survival (OS, 1998-2007) rates were collected from the Surveillance Epidemiology and End Result (SEER) registry (covering 28% of US patients) for common CNS tumours in age epochs ranging 0-80 years. Patients with histologically confirmed, ICD-03 coded, first tumours, were included. Mortality was defined as any cause of death within 1- or 5-years of diagnosis. Results were statistically analysed by Incidence Rate Ratio (IRR), Kaplan-Meier and Log Rank (Cox Proportional Regression Hazard) Testing (p < 0.05). RESULTS: Significantly higher incidence was observed in males with grade II astrocytomas (IRR 1.19), high grade gliomas (IRR 1.18-1.26), oligodendrogliomas (IRR 1.12), lymphoma (IRR 1.18), embryonal (IRR 1.17-1.21), and GCTs (IRR 1.51) (all p < 0.05). No significant difference in incidence was seen between gender in pilocytics, ependymomas and meningiomas. 1- and 5-year OS was better in; older females with meningiomas, oligodendrogliomas and ependymomas; younger males with anaplastic astrocytomas. 5-year OS was better in; females aged <5 years with ependymomas, females aged 10-24 years with medulloblastomas; females aged 20-39 with grade II astrocytomas. CONCLUSION: Interrogating population-based registries such as SEER minimises bias and provides credible data. Gender is a significant factor in predisposing to certain CNS tumours and treatment response - possibly through epigenetic and hormonal differences. Further investigation is needed.
AB1078 Colchicine Use and Risk of Myocardial Infarction among Gout Patients - A General Population Study: Table 1.
Authors: M. Dubreuil, C. Peloquin, Y. Zhang, T. Neogi, H.K. Choi
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> A recent randomized trial demonstrated a 77% reduced risk of myocardial infarction (MI) among adults with known coronary artery disease treated with long-term low dose colchicine.<sup>1</sup> Whether colchicine reduces the risk of incident MI in gout patients is unknown. <h3>Objectives</h3> We examined the association of colchicine use and incident MI among gout patients using data from a general population database (The Health Improvement Network [THIN]). <h3>Methods</h3> Included were adults aged 18-89 years who had been enrolled in THIN ≥2 years and had no history of MI. We identified persons who developed gout from 2000-2012, and identified MI cases. In a nested case-control analysis, we matched each gout patient with MI, to 5 gout patients without MI based on age and sex. Colchicine use was categorized as current (prescription within 30 days of index date), recent (31-179 days), past (≥180 days) or never. We conducted a conditional logistic regression model to adjust for potential confounders of MI. We also examined the number of colchicine prescriptions issued in the year prior to the index date in a case-control analysis. <h3>Results</h3> Among 55,509 persons with incident gout, there were 974 cases of MI, matched to 4762 controls. The adjusted ORs for current, recent and past colchicine use (relative to non-use) were 0.96, 1.49, and 1.12 respectively. The adjusted ORs for 1, 2, 3-5, and &gt;6 prescriptions were 1.31 (95% CI 0.97-1.78), 1.50 (0.88-2.55), 1.35 (0.72-2.55) and 0.62 (0.18-2.10) respectively. <h3>Conclusions</h3> In this large observational general population study, colchicine use was not associated with a reduced risk of MI among persons with gout. However, colchicine use in this population was generally sporadic (likely for gout flares), rather than continuous. We cannot rule out the potential for confounding by indication. Future studies should identify a larger sample of continuous colchicine users to clarify its potential cardioprotective role in gout. <h3>References</h3> Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404-10. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1664
Phase III trials of anamorelin in patients with advanced non-small cell lung cancer (NSCLC) and cachexia (ROMANA 1 and 2).
Authors: Jennifer S. Temel, David Christopher Currow, Kenneth Fearon, Ying Yan, John Friend, Amy Pickar Abernethy
Journal: Journal of Clinical Oncology (2015)

9500 Background: Patients with advanced cancers frequently experience anorexia and cachexia, which is associated with decreased functional status and poor tolerance of chemotherapy. ROMANA 1 and 2 were two randomized, double blind trials evaluating the effect of anamorelin, a ghrelin receptor agonist, on cachexia in patients with advanced NSCLC. Methods: We randomly assigned 484 patients (ROMANA 1) and 495 patients (ROMANA 2) with inoperable stage III or stage IV NSCLC and cachexia ( ≥ 5% weight loss within prior 6 months or BMI < 20 kg/m2) to placebo or anamorelin 100 mg orally once daily. Co-primary efficacy endpoints were the change in lean body mass and handgrip strength from baseline over 12 weeks. Secondary endpoints included change in body weight and symptom burden over 12 weeks and pooled survival from ROMANA 1 and ROMANA 2. Exploratory analyses evaluated change in total body mass and fat mass from baseline to 12 weeks. Results: Patients assigned to anamorelin experienced an increase in lean body mass compared to those assigned to placebo in ROMANA 1 (1.10 vs -0.44 kg, p < 0.001) and ROMANA 2 (0.75 vs -0.96 kg, p < 0.001), but no difference in handgrip strength. Patients assigned to anamorelin also had a significant increase in body weight (2.2 vs 0.14 kg, p < 0.001) and (0.95 vs -0.57 kg, p < 0.001) and improvement in their anorexia/cachexia symptoms (4.12 vs 1.92, p < 0.001) and (3.48 vs 1.34, p = 0.002) in ROMANA 1 and 2, respectively. Exploratory analysis demonstrated an increase in total body mass (2.87 vs 0.07 kg, p < 0.001) and (2.04 vs -0.59 kg, p < 0.001), and fat mass (1.21 vs -0.13 kg, p < 0.001) and (0.77 vs 0.09 kg, p = 0.012) for anamorelin versus placebo in the two studies, respectively. Anamorelin was well tolerated with hyperglycemia and diabetes as the most frequent drug-related adverse events ( ≤ 5%). Median 1-year survival was not different between study arms. Conclusions: Anamorelin increased lean body mass, body weight, total body mass and fat mass indicating anabolic activity and restoration of energy balance in patients with advanced NSCLC. Patients also experienced significant improvement in anorexia/cachexia symptoms. Anamorelin was well tolerated, with similar pooled survival between study arms. Clinical trial information: NCT01387269 and NCT01387282.
Recurrent Pulmonary Embolism and Cor Pulmonale
Authors: Felix G. Fleischner
Journal: New England Journal of Medicine (1967)

CONSIDERABLE progress has been made in recent years in the understanding of thromboembolic disease and also in the ability to diagnose acute pulmonary embolism. Radiologists have learned to interpret plain roentgenograms better and, in addition, to rely more on the newer documentary methods of pulmonary angiography and lung scanning. These advances are paralleled by a general, broader appreciation of the common occurrence of pulmonary embolism. Greater attention is presently being directed toward the frequent occurrence of chronic embolization and its sequelae, chronic hypertension and cor pulmonale.1 2 3 4 5 6 7 The work of the radiologist is made difficult by the fact that he is . . .
AB0549 Discontinuation of methotrexate (MTX) in rheuamtoid arthritis (RA) patients receiving tocilizumab (TCZ)
Authors: K. Nishimura, R. Sakai, T. Kondo, T. Kurasawa, A. Okuyama, E. Nishi, Y. Shirai, H. Takei, H. Nagasawa, K. Amano
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Although MTX is the anchor drug for the managemant of RA because of its effectiveness and affordability, some patients taking MTX develop liver dysfunction, nausea and bone marrow suppression. In addition, a few patients treated with MTX have life-threatening interstitial pneumonitis and lymphoproliferative disorders that may possibly progress to lymphoma if MTX is continued. TCZ is the only biological agent that has the evidence of efficacy for RA without concomitant MTX based on the clinical studies. This will suggest that MTX can be discontinued in some patients with RA treated with TCZ successfully. <h3>Objectives</h3> To clarify clinical characteristics of RA patients who were able to quit taking MTX within 52 weeks after the start of TCZ. <h3>Methods</h3> Clinical records of 89 RA patients (11 males, 78 females) in whom TCZ was newly initiated with MTX in our institute were retrospectively reviewed. <h3>Results</h3> MTX was discontinued in 23 of 89 patients(26%). Background of the MTX-discontinued group (n=23) and the MTX-continued group (n=66) at the start of TCZ, mean age was 62.2 and 56.3 years old (p&lt;o.o5), mean disease duration was 119 and 120 months (n.s.), mean MTX dose was 7.0 and 7.8 mg/week (n.s.), mean DAS28-ESR was 6.20 and 5.50 (p&lt;o.o5), respectively. At week 52 in the MTX-discontinued group and in the MTX-continued group, mean DAS28-ESR was 2.87 and 2.80(n.s.), CDAI was improved from 28.6 to 9.5 and from 24.6 to 10.7, CDAI remission ratio was 26% and 21%, HAQ-DI was reduced from 1.68 to 1.10 and from 1.47 to 1.16, respectively. All these values were not significant between 2 groups. <h3>Conclusions</h3> MTX was discontinued more frequently in the elderly patients possibly due to considering patients’ safety by their attending doctors, which may be good for the prevention of previously mentioned MTX-induced adverse events. In addition, though MTX-discontinued group patients had higher disease activity, TCZ was equally effective as MTX-continued group patients. TCZ mono-therapy seems to be useful to maintain the low disease activity. It might be recommended to stop MTX after achieving low disease activity or remission with tocilizumab in RA patients, especially elders. <h3>Disclosure of Interest</h3> K. Nishimura Grant/Research support from: Chugai Pharma, R. Sakai Grant/Research support from: Chugai Pharma, T. Kondo Grant/Research support from: Chugai Pharma, T. Kurasawa Grant/Research support from: Chugai Pharma, A. Okuyama Grant/Research support from: Chugai Pharma, E. Nishi Grant/Research support from: Chugai Pharma, Y. Shirai Grant/Research support from: Chugai Pharma, H. Takei Grant/Research support from: Chugai Pharma, H. Nagasawa Grant/Research support from: Chugai Pharma, K. Amano Grant/Research support from: Chugai Pharma
554 EPIDEMIOLOGICAL, VIROLOGICAL AND CLINICAL FEATURES OF 112 HEPATITIS E VIRUS INFECTIONS DIAGNOSED OVER A 5-YEAR PERIOD IN SOUTH-EASTERN FRANCE
Authors: P. Colson, V. Moal, M. Kaba, P. Borentain, M. Mola, N. Tivoli, A. Motte, R. Gérolami
Journal: Journal of Hepatology (2012)
Endoscopic closure of acute Boerhaave’s syndrome with an over-the-scope clip
Authors: Sudheer Vinnamala, Vinod Menon, Ramesh Arasaradnam, Jayne Eaden, John Wong, Jayan Mannath
Journal: Endoscopy (2014)

A 63-year-old man attended the accident and emergency department with chest pain and breathlessness following an episode of severe vomiting after excess alcohol intake. Clinical examination and chest radiography confirmed a left-sided tension pneumothorax requiring an emergency thoracocentesis and chest drain placement. Computed tomography (CT) scan with intravenous contrast showed a left-sided pneumothorax and pneumomediastinum, which suggested the possibility of an esophageal rupture in the absence of external trauma. A CT scan with oral contrast performed subsequently, showed leakage of contrast from the lower esophagus into the left pleural space, consistent with lower esophageal leak due to Boerhaave's syndrome ([Fig. 1]).
Assessing the Burden of Cancer Patient Homecare
Authors: L. Fintor, J. Flach
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article Assessing the Burden of Cancer Patient Homecare Get access Lou Fintor, Lou Fintor Search for other works by this author on: Oxford Academic PubMed Google Scholar Jen Flach Jen Flach Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 10, 20 May 1992, Pages 752–753, https://doi.org/10.1093/jnci/84.10.752 Published: 20 May 1992
Differentiation of Cardiac Tumor From Thrombus by Combined MRI and F-18 FDG PET Imaging
Authors: JEFFREY J. PLUTCHOK, LAWRENCE M. BOXT, JUDAH WEINBERGER, RASHID FAWWAZ, WILLIAM H. SHERMAN, RONALD L. VAN HEERTUM
Journal: Clinical Nuclear Medicine (1998)

FDG-PET imaging was performed to evaluate a right ventricular mass seen on transthoracic echocardiogram and gated cardiac MRI in a patient with metastatic breast carcinoma. There was intense FDG localization in the mass, characterizing the mass as a highly metabolic tumor. A transjugular biopsy confirmed a sarcomatous-type tumor.
Renal Damage Following Intravascular Hemolysis
Authors: E. Langdon Burwell, Thomas D. Kinney, Clement A. Finch
Journal: New England Journal of Medicine (1947)

THE sequence of hemoglobinuria followed by oliguria and anuria is well known. The observations reported below are especially concerned with the medical management of the anuric patient and with the functional and anatomic reversibility of the renal lesion produced.In the case of anuria following massive intravascular hemolysis reported below, the patient recovered from the episode only to succumb three months later to homologous serum hepatitis. During the intervening period, the renal function showed steady improvement as evidenced by clinical and laboratory tests. Autopsy offered a unique opportunity to correlate the residual anatomic lesions with the clinical picture. In a . . .
IDARUCIZUMAB FOR REVERSAL OF THE ANTICOAGULANT EFFECTS OF DABIGATRAN IN PATIENTS IN AN EMERGENCY SETTING OF MAJOR BLEEDING, URGENT SURGERY, OR INTERVENTIONS
Authors: Charles V. Pollack, Paul Reilly, John Eikelboom, Stephan Glund, Fredrik Gruenenfelder, Richard Bernstein, Menno Huisman, Elaine Hylek, Pieter W. Kamphuisen, Jörg Kreuzer, Jerrold Levy, Frank Sellke, Joachim Stangier, Thorsten Steiner, Bushi Wang, Chak Wah Kam, Jeffrey Weitz
Journal: Journal of the American College of Cardiology (2016)
False-Positive Ventilation-Perfusion Scan in a Patient with a Transplanted Lung
Authors: DIMA HAMMOUD, BENNETT CHIN
Journal: Clinical Nuclear Medicine (2003)

A false-positive ventilation perfusion (V/Q) scan in a patient with a transplanted lung and secondary pulmonary artery stenosis is reported. The patient was examined for tachypnea and shortness of breath after single lung transplantation. A V/Q scan revealed multiple perfusion defects in the transplanted lung, with no corresponding ventilation defects. A pulmonary angiogram revealed pulmonary artery stenosis and no pulmonary emboli. The authors describe a false-positive V/Q scan in a patient after lung transplantation.
Abstract 2632: Syrbactin, a novel proteasome inhibitor class, induces apoptosis and autophagy in neuroblastoma
Authors: Andre S. Bachmann, Crystal R. Archer, Dana-Lynn T. Koomoa, Jerome Clerc, Mariko Shimizu, Markus Kaiser, Barbara Schellenberg, Robert Dudler
Journal: Cancer Research (2010)

Abstract Syrbactins belong to a new class of proteasome inhibitors which include syringolins and glidobactins. These small molecules are structurally distinct from other, well-established proteasome inhibitors, and bind the eukaryotic 20S proteasome by a novel mechanism. In this study, we examined the effects of syringolin A (SylA) and glidobactin A (GlbA) as well as two synthetic SylA-analogs (SylA-PEG and SylA-LIP) in human neuroblastoma (SK-N-SH), human multiple myeloma (MM1.S, MM1.RL, and U266), and human ovarian cancer (SKOV3) cells. While all four syrbactins inhibited cell proliferation in a dose-dependent manner, GlbA was most potent in both dexamethasone-sensitive MM1.S cells (IC50: 0.004 µM) and dexamethasone-resistant MM1.RL cells (IC50: 0.005 µM). Syrbactins also inhibited the chymotrypsin-like proteasome activity in a dose-dependent fashion, and GlbA was most effective in SK-N-SH cells (IC50: 0.015 µM). The GlbA-promoted inhibition of proteasomal activity in SK-N-SH cells resulted in the accumulation of ubiquitinated proteins and tumor suppressor protein p53, and led to apoptotic cell death. Strikingly, GlbA treatment also promoted the activation of Akt/PKB via phosphorylation at residue Ser473 and induced autophagy as judged by the presence of the lipidated form of microtubule-associated protein 1 light chain 3 (LC3) and autophagosomes. Collectively, our data suggest that syrbactins belong to a new and effective proteasome inhibitor class which promotes cell death. Proteasome inhibition is a promising strategy for targeted anticancer therapy and syrbactins are a new class of inhibitors which provide a structural platform for the development of novel, proteasome inhibitor-based drug therapeutics. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2632.
Neuron-Specific Enolase-- A Serum marker for Malignanat Melanoma
Authors: J. LORENZ, W. DIPPOLD
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article Neuron-Specific Enolase— A Serum marker for Malignanat Melanoma Get access JOACHIM LORENZ, JOACHIM LORENZ 3rd Medical ClinicD-6500 Mainz Federal Republic of Germany Search for other works by this author on: Oxford Academic PubMed Google Scholar WOLFGANG DIPPOLD WOLFGANG DIPPOLD 1st Medical Clinic University Hospital Johannes Gutenberg UniversityD-6500 Mainz Federal Republic of Germany Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 22, 15 November 1989, Pages 1754–1755, https://doi.org/10.1093/jnci/81.22.1754 Published: 15 November 1989
Fetal Fibronectin in Cervical and Vaginal Secretions as a Predictor of Preterm Delivery
Authors: Charles J. Lockwood, Andrew E. Senyei, M. Renate Dische, David Casal, Kumudini D. Shah, Swan N. Thung, Lynn Jones, Liane Deligdisgh, Thomas J. Garite
Journal: New England Journal of Medicine (1991)

Preterm delivery is the leading cause of neonatal mortality in the United States, but efforts to address the problem are hampered by the inability to predict accurately which pregnancies are at risk. We postulated that damage to the fetal membranes may release fetal fibronectin into the cervix and vagina, giving rise to a biochemical marker for preterm delivery.
EFFECT OF SEVERE LEFT VENTRICULAR DYSFUNCTION ON OUTCOMES AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT VERSUS SURGICAL AORTIC VALVE REPLACEMENT: A PROPENSITY SCORE REGRESSION ANALYSIS
Authors: Vinod H. Thourani, Richard C. Gilmore, Jose Condado Contreras, Hanna A. Jensen, Jose Binongo, Qunna Li, Eric Sarin, Chandan Devireddy, Bradley Leshnower, Kreton Mavromatis, Robert Guyton, James Stewart, Stamatios Lerakis, Amy Simone, Patricia Keegan, Peter Block, Vasilis Babaliaros
Journal: Journal of the American College of Cardiology (2015)
How and what does the cerebellum learn?
Authors: Peter F. C. Gilbert
Journal: Behavioral and Brain Sciences (1996)

Information for motor learning is likely to be stored by groups of Purkinje cells in the cerebellum as suggested by HOUK et al., though their proposal that Purkinje cells act as bistable elements is open to question. THACH's excellent article breaks new ground on what type of information the cerebellum may store. I have queries on whether the cerebellum can generate "thought" or is likely to engage in the purely mental learning of movements, [HOUK et al.; THACH]
683 TGF-b, CYFRA21_1, IGF2 AND IL_8 SERUM LEVELS CATEGORIZE HEPATOCELLULAR CARCINOMA (HCC) WITH FASTER GROWTH AND SHORTER SURVIVAL
Authors: E. Villa, R. Critelli, E. Turola, B. Lei, E. Bertolini, F. Milosa, S. Colopi, S. Ballestri, A. Berselli, E. Baldelli, E. Meschiari, G.E. Gerunda, G. Giannelli, P. Loria
Journal: Journal of Hepatology (2013)
POSITRON EMISSION TOMOGRAPHY STRESS MYOCARDIAL BLOOD FLOW PREDICTS VENTRICULAR TACHYARRHYTHMIA IN PATIENTS WITH AN IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR
Authors: Todd Rosenthal, Saima Karim, Freddy Abi Samra, Michael Bernard, Sammy Khatib, Glenn Polin, Eiman Jahangir, Robert Bober, Daniel Morin
Journal: Journal of the American College of Cardiology (2015)